Aktienanalyse zu Amarin Corporation PLC (AMRN)AMRNAmarin Corporation PLC

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Amarin Corporation PLC is currently a hold. The stock is trading at $12.13, which is below the analyst price target of $13, indicating potential upside. However, the company has faced a 42% year-over-year revenue decline in Q2 2026 and has a forward P/E ratio of 500, suggesting significant uncertainty in future earnings. The RSI is at 51.108, indicating a neutral momentum, while the stock is positioned at 14.5% of its 52-week range, showing limited immediate upside potential. The main risk is the ongoing pressure on the U.S. business, which could hinder growth despite international market gains.

5 analysts cover AMRN: 5 rate it Buy, 0 Hold and 0 Sell.